Phaxiam Therapeutics Obtains Authorizations To Launch Its Phase 1 Study In Endocarditis Infections Caused By Staphylococcus Aureus
Portfolio Pulse from Benzinga Newsdesk
Phaxiam Therapeutics (PHXM) has received approval from the French National Agency for the Safety of Medicines and Health Products and the South-East II-Lyon Ethics Committee to launch its Phase 1 study on endocarditis infections caused by Staphylococcus aureus. The study is expected to start in Q4 2023 with 12 patients across 4 French centers. The first results are expected in mid-2024. The study aims to assess the safety of intravenous administration of PHAXIAM phages and their pharmacokinetics in the blood.
October 24, 2023 | 8:39 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Phaxiam Therapeutics has received approval to launch its Phase 1 study on endocarditis infections. This could potentially open up a new treatment avenue for the company, pending successful results.
The approval of the Phase 1 study is a significant milestone for Phaxiam Therapeutics as it allows the company to potentially develop a new treatment for endocarditis infections. If the study yields positive results, it could lead to increased investor interest and a potential boost in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100